Andrew L. Wilson, PharmD, FASHP, Vice President, McKesson 340B Solutions

Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.